Cristiano Gonçalves Pereira
TítuloCitado porAno
Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma
YNV Gopal, H Rizos, G Chen, W Deng, DT Frederick, ZA Cooper, ...
Cancer research 74 (23), 7037-7047, 2014
Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target
G Chen, N Chakravarti, K Aardalen, AJ Lazar, MT Tetzlaff, B Wubbenhorst, ...
Clinical Cancer Research 20 (21), 5537-5546, 2014
RMEL3, a novel BRAFV600E-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma
L Goedert, CG Pereira, J Roszik, JR Plaça, C Cardoso, G Chen, W Deng, ...
Oncotarget 7 (24), 36711, 2016
Novel primate-specific genes, RMEL 1, 2 and 3, with highly restricted expression in melanoma, assessed by new data mining tool
JF Sousa, R Torrieri, RR Silva, CG Pereira, V Valente, E Torrieri, ...
PloS one 5 (10), e13510, 2010
Different isolates from Leishmania braziliensis complex induce distinct histopathological features in a murine model of infection
CG Pereira, ALN Silva, P de Castilhos, EC Mastrantonio, RA Souza, ...
Veterinary parasitology 165 (3-4), 231-240, 2009
Ten years of iPSC: clinical potential and advances in vitro hematopoietic differentiation
BCMF Paes, PD Moco, CG Pereira, GS Porto, EM de Sousa Russo, ...
Cell biology and toxicology 33 (3), 233-250, 2017
A typical presentation of cutaneous leishmaniasis after renal transplantation
FA Vinhal, SR Afonso-Cardoso, AG Silva, CG Pereira, W Sousa, ...
Nephrology Dialysis Transplantation 22 (12), 3674-3674, 2007
Patent mining and landscaping of emerging recombinant factor VIII through network analysis
CG Pereira, V Picanco-Castro, DT Covas, GS Porto
Nature biotechnology 36 (7), 585-590, 2018
The scientific information provided through patents and its limited use in scientific research at universities
CG Pereira, RR Da Silva, GS Porto
Brazilian Journal of Science and Technology 2 (1), 2, 2015
Effects of Bothrops moojeni venom on Leishmania amazonensis promastigote forms
P Castilhos, CG Pereira, ALN Silva, DR Napolitano, F Oliveira, MA Souza
Journal of Venomous Animals and Toxins including Tropical Diseases 17 (2 …, 2011
Uncovering innovation features and emerging technologies in molecular biology through patent analysis
CG Pereira, GS Porto
Recombinant Glycoprotein Production, 15-34, 2018
An IT Value Management Capability Model for Portuguese Universities: A Delphi Study
C Pereira, C Ferreira, L Amaral
Procedia computer science 138, 612-620, 2018
The lncRNA RMEL3 protects immortalized cells from serum withdrawal‐induced growth arrest and promotes melanoma cell proliferation and tumor growth
C Cardoso, RB Serafim, A Kawakami, C Gonçalves Pereira, J Roszik, ...
Pigment cell & melanoma research 32 (2), 303-314, 2019
Forecasting of emerging therapeutic monoclonal antibodies patents based on a decision model
CG Pereira, JR Lavoie, E Garces, F Basso, M Dabić, GS Porto, T Daim
Technological Forecasting and Social Change 139, 185-199, 2019
Technological cooperation network in biotechnology: Analysis of patents with Brazil as the priority country
CG Pereira, RR Da Silva, JR Lavoie, GS Porto
Innovation & Management Review 15 (4), 416-434, 2018
The involvement of heparin in retinal infection by Toxoplasma gondii in a chick model revealed an ontogenetic-dependent pattern
EC Mastrantonio, CD Lopes, CG Pereira, NM Silva, BB Fonseca, ...
Parasitology international 63 (2), 337-340, 2014
Reatividade sorológica de cães frente a antígenos de três espécies de Leishmania
Horizonte Científico1 1, 1-28, 2007
Assessment of biotechnologies: a therapeutic monoclonal antibody emerging score
CG Pereira, J Lavoie, E Garces, M Dabic, GS Porto, T Daim
2018 IEEE Technology and Engineering Management Conference (TEMSCON), 1-6, 2018
RMEL3, a long noncoding RNA, induces tumor malignancy through the MAPK and PI3K pathways in BRAFV600E melanomas
L Goedert, CG Pereira, J Roszik, JR Plaça, C Cardoso, G Chen, W Deng, ...
Abstracts, 2016
Influência de potenciais lncRNAs de expressão restrita ao melanoma (RMEL) na regulação de vias canônicas da melanomagênese
CG Pereira, EM Espreafico
O sistema não pode executar a operação agora. Tente novamente mais tarde.
Artigos 1–20